Literature DB >> 24088994

Interleukin 6 mediates neuroinflammation and motor coordination deficits after mild traumatic brain injury and brief hypoxia in mice.

Sung H Yang1, Matt Gangidine, Timothy A Pritts, Michael D Goodman, Alex B Lentsch.   

Abstract

Traumatic brain injury (TBI) is a leading cause of mortality and disability. Acute postinjury insults after TBI, such as hypoxia, contribute to secondary brain injury and worse clinical outcomes. The functional and neuroinflammatory effects of brief episodes of hypoxia experienced following TBI have not been evaluated. Our previous studies have identified interleukin 6 (IL-6) as a potential mediator of mild TBI-induced pathology. In the present study, we sought to determine the effects of brief hypoxia on mild TBI and whether IL-6 played a role in the neuroinflammatory and functional deficits after injury. A murine model of mild TBI was induced by a weight drop (500 g from 1.5 cm). After injury, mice were exposed to immediate hypoxia (FIO2 = 15.1%) or normoxia (FIO2 = 21%) for 30 min. Serum and brain samples were analyzed for inflammatory cytokines 24 h after TBI. Neuron-specific enolase was measured as a serum biomarker of brain injury. Evaluation of motor coordination was performed for 5 days after TBI using a rotarod device. In some animals, anti-IL-6 was administered following TBI and hypoxia to neutralize systemic IL-6. Mice undergoing TBI had significant increases in brain injury. Exposure to brief hypoxia after TBI resulted in a more than 5-fold increase in serum neuron-specific enolase. This increase was associated with increases in serum and brain cytokine expression, suggesting that brief hypoxia exacerbates systemic and brain inflammation. Neutralization of IL-6 suppressed postinjury neuroinflammation and neuronal injury. In addition, TBI and hypoxia induced significant motor coordination deficits that were completely abrogated by IL-6 blockade. Exposure to hypoxia after TBI induces neuroinflammation and brain injury. These changes can be mitigated by neutralization of systemic IL-6. Interleukin 6 blockade also corrected the TBI-induced deficit in motor coordination. These data suggest that systemic IL-6 modulates the degree of neuroinflammation and contributes to reduced motor coordination after mild TBI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24088994      PMCID: PMC4218737          DOI: 10.1097/SHK.0000000000000037

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  23 in total

1.  Traumatic brain injury hospitalizations of U.S. army soldiers deployed to Afghanistan and Iraq.

Authors:  Barbara E Wojcik; Catherine R Stein; Karen Bagg; Rebecca J Humphrey; Jason Orosco
Journal:  Am J Prev Med       Date:  2010-01       Impact factor: 5.043

2.  Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injury.

Authors:  Eduardo Miñambres; Arantxa Cemborain; Pablo Sánchez-Velasco; Marco Gandarillas; Genaro Díaz-Regañón; Ubaldo Sánchez-González; Francisco Leyva-Cobián
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

3.  A murine model of mild traumatic brain injury exhibiting cognitive and motor deficits.

Authors:  Sung H Yang; Josh Gustafson; Matt Gangidine; David Stepien; Rebecca Schuster; Timothy A Pritts; Michael D Goodman; Daniel G Remick; Alex B Lentsch
Journal:  J Surg Res       Date:  2013-04-18       Impact factor: 2.192

4.  The epidemiology and impact of traumatic brain injury: a brief overview.

Authors:  Jean A Langlois; Wesley Rutland-Brown; Marlena M Wald
Journal:  J Head Trauma Rehabil       Date:  2006 Sep-Oct       Impact factor: 2.710

5.  Prehospital hypoxia affects outcome in patients with traumatic brain injury: a prospective multicenter study.

Authors:  John H Chi; M Margaret Knudson; Mary J Vassar; Mary C McCarthy; Michael B Shapiro; Susan Mallet; John J Holcroft; Hugh Moncrief; Jennifer Noble; David Wisner; Krista L Kaups; Lynn D Bennick; Geoffrey T Manley
Journal:  J Trauma       Date:  2006-11

6.  Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.

Authors:  Georgene W Hergenroeder; Anthony N Moore; J Philip McCoy; Leigh Samsel; Norman H Ward; Guy L Clifton; Pramod K Dash
Journal:  J Neuroinflammation       Date:  2010-03-11       Impact factor: 8.322

Review 7.  Motor and cognitive function evaluation following experimental traumatic brain injury.

Authors:  Scott T Fujimoto; Luca Longhi; Kathryn E Saatman; Valeria Conte; Nino Stocchetti; Tracy K McIntosh
Journal:  Neurosci Biobehav Rev       Date:  2004-07       Impact factor: 8.989

8.  Both hypoxemia and extreme hyperoxemia may be detrimental in patients with severe traumatic brain injury.

Authors:  Daniel P Davis; William Meade; Michael J Sise; Frank Kennedy; Fred Simon; Gail Tominaga; John Steele; Raul Coimbra
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

9.  The preflight evaluation. A comparison of the hypoxia inhalation test with hypobaric exposure.

Authors:  T A Dillard; L K Moores; K L Bilello; Y Y Phillips
Journal:  Chest       Date:  1995-02       Impact factor: 9.410

Review 10.  Hypoxia altitude simulation test.

Authors:  C Jessica Dine; Mary Elizabeth Kreider
Journal:  Chest       Date:  2008-04       Impact factor: 9.410

View more
  49 in total

Review 1.  In vitro and in vivo neuronal electrotaxis: a potential mechanism for restoration?

Authors:  Ali Jahanshahi; Lisa-Maria Schönfeld; Evi Lemmens; Sven Hendrix; Yasin Temel
Journal:  Mol Neurobiol       Date:  2013-11-16       Impact factor: 5.590

Review 2.  Current status of fluid biomarkers in mild traumatic brain injury.

Authors:  Jacqueline R Kulbe; James W Geddes
Journal:  Exp Neurol       Date:  2015-05-14       Impact factor: 5.330

3.  Acid Sphingomyelinase Inhibition Mitigates Histopathological and Behavioral Changes in a Murine Model of Traumatic Brain Injury.

Authors:  Grace M Niziolek; Ryan M Boudreau; Jennifer Baker; Lou Ann Friend; Amy T Makley; Michael J Edwards; Erich Gulbins; Michael D Goodman
Journal:  J Neurotrauma       Date:  2020-05-04       Impact factor: 5.269

Review 4.  Translational approach towards determining the role of cerebral autoregulation in outcome after traumatic brain injury.

Authors:  William M Armstead; Monica S Vavilala
Journal:  Exp Neurol       Date:  2019-03-27       Impact factor: 5.330

5.  Gene co-expression networks identify Trem2 and Tyrobp as major hubs in human APOE expressing mice following traumatic brain injury.

Authors:  Emilie L Castranio; Anais Mounier; Cody M Wolfe; Kyong Nyon Nam; Nicholas F Fitz; Florent Letronne; Jonathan Schug; Radosveta Koldamova; Iliya Lefterov
Journal:  Neurobiol Dis       Date:  2017-05-11       Impact factor: 5.996

6.  Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation.

Authors:  G Meneses; G Gevorkian; A Florentino; M A Bautista; A Espinosa; G Acero; G Díaz; A Fleury; I N Pérez Osorio; A Del Rey; G Fragoso; E Sciutto; H Besedovsky
Journal:  Clin Exp Immunol       Date:  2017-09-07       Impact factor: 4.330

7.  The effect of mild traumatic brain injury on peripheral nervous system pathology in wild-type mice and the G93A mutant mouse model of motor neuron disease.

Authors:  T M Evans; C A Jaramillo; K Sataranatarajan; L Watts; M Sabia; W Qi; H Van Remmen
Journal:  Neuroscience       Date:  2015-04-25       Impact factor: 3.590

8.  The P2X7 receptor links mechanical strain to cytokine IL-6 up-regulation and release in neurons and astrocytes.

Authors:  Wennan Lu; Farraj Albalawi; Jonathan M Beckel; Jason C Lim; Alan M Laties; Claire H Mitchell
Journal:  J Neurochem       Date:  2017-05       Impact factor: 5.372

Review 9.  Cerebral Blood Flow Autoregulation and Dysautoregulation.

Authors:  William M Armstead
Journal:  Anesthesiol Clin       Date:  2016-09

10.  Autophagy protects against cerebral ischemic reperfusion injury by inhibiting neuroinflammation.

Authors:  Hao Zha; Yaodong Fan; Li Yang; Mei Yin; Wei Miao; Jin He; Ying Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.